These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1493850)

  • 1. Pharmacokinetics of temocapril hydrochloride, a novel angiotensin converting enzyme inhibitor, in renal insufficiency.
    Nakashima M; Yamamoto J; Shibata M; Uematsu T; Shinjo H; Akahori T; Shioya H; Sugiyama K; Kawahara Y
    Eur J Clin Pharmacol; 1992; 43(6):657-9. PubMed ID: 1493850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency.
    Oguchi H; Miyasaka M; Koiwai T; Tokunaga S; Hora K; Sato K; Yoshie T; Shioya H; Furuta S
    Clin Pharmacokinet; 1993 May; 24(5):421-7. PubMed ID: 8504625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose pharmacokinetics of temocapril and temocapril diacid in subjects with varying degrees of renal impairment.
    Sierakowski B; Püchler K; Witte PU; Renneisen K; Roots I
    Eur J Clin Pharmacol; 1997; 53(3-4):215-20. PubMed ID: 9476034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans.
    Suzuki H; Kawaratani T; Shioya H; Uji Y; Saruta T
    Biopharm Drug Dispos; 1993 Jan; 14(1):41-50. PubMed ID: 8427943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of temocapril, an ACE inhibitor with preferential biliary excretion, in patients with impaired liver function.
    Furuta S; Kiyosawa K; Higuchi M; Kasahara H; Saito H; Shioya H; Oguchi H
    Eur J Clin Pharmacol; 1993; 44(4):383-5. PubMed ID: 8513851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of temocapril and temocaprilat after 14 once daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment.
    Püchler K; Eckl KM; Fritsche L; Renneisen K; Neumayer HH; Sierakowski B; Lavrijssen AT; Thomsen T; Roots I
    Br J Clin Pharmacol; 1997 Dec; 44(6):531-6. PubMed ID: 9431827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile.
    Yasunari K; Maeda K; Nakamura M; Watanabe T; Yoshikawa J; Asada A
    Cardiovasc Drug Rev; 2004; 22(3):189-98. PubMed ID: 15492767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.
    Hoyer J; Schulte KL; Lenz T
    Clin Pharmacokinet; 1993 Mar; 24(3):230-54. PubMed ID: 8462229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor.
    Oizumi K; Koike H; Sada T; Miyamoto M; Nishino H; Matsushita Y; Iijima Y; Yanagisawa H
    Jpn J Pharmacol; 1988 Nov; 48(3):349-56. PubMed ID: 2851680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of temocapril during repeated dosing in elderly hypertensive patients.
    Arakawa M; Sasaki M; Ohmori M; Harada K; Fujimura A
    Eur J Clin Pharmacol; 2001; 56(11):775-9. PubMed ID: 11294366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of transport mechanism of prodrugs and parent drugs formed by intracellular metabolism in Caco-2 cells with modified carboxylesterase activity: temocapril as a model case.
    Ohura K; Nozawa T; Murakami K; Imai T
    J Pharm Sci; 2011 Sep; 100(9):3985-94. PubMed ID: 21618543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR).
    Ishizuka H; Konno K; Naganuma H; Sasahara K; Kawahara Y; Niinuma K; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1304-11. PubMed ID: 9067317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic effects of temocapril in hypertensive patients with diabetes mellitus type 2.
    Lerch M; Weidmann P; Ho MP; Gerber P; Eckenberger P; Kaemmereit A; Teuscher AU
    J Cardiovasc Pharmacol; 1999 Apr; 33(4):527-33. PubMed ID: 10218721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition and safety of omapatrilat in subjects with renal impairment.
    Sica DA; Liao W; Gehr TW; Khan S; Jemal M; Delaney CL; Ferreira IM; Malhotra BK
    Clin Pharmacol Ther; 2000 Sep; 68(3):261-9. PubMed ID: 11014407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with chronic renal failure.
    Hoogkamer JF; Kleinbloesem CH; Nokhodian A; Ouwerkerk MJ; Lankhaar G; Ungethüm W; Kirch W
    Eur J Clin Pharmacol; 1998 Mar; 54(1):59-61. PubMed ID: 9591932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients.
    Püchler K; Sierakowski B; Roots I
    Br J Clin Pharmacol; 1998 Oct; 46(4):363-7. PubMed ID: 9803985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and acute effect on the renin-angiotensin system of delapril in patients with chronic renal failure.
    Shionoiri H; Yasuda G; Abe Y; Yoshimura H; Kaneko Y; Shindo Y
    Clin Nephrol; 1987 Feb; 27(2):65-70. PubMed ID: 3030595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic drug interactions with ACE inhibitors.
    Shionoiri H
    Clin Pharmacokinet; 1993 Jul; 25(1):20-58. PubMed ID: 8354016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of different clinical and biochemical correlates to assess angiotensin converting enzyme inhibition.
    Delacrétaz E; Nussberger J; Püchler K; Wood AJ; Robinson PR; Waeber B; Brunner HR
    J Cardiovasc Pharmacol; 1994 Sep; 24(3):479-85. PubMed ID: 7528305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride.
    Friehe H; Ney P
    Arzneimittelforschung; 1997 Feb; 47(2):132-44. PubMed ID: 9079232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.